IntroductionSlowing growth continues in major developed markets, prompted by generic erosion of branded sales and increasing regulatory and cost containment pressures. Expansion into emerging Asia Pacific (APAC) markets is appealing not only because of their rapid growth and sizeable patient populations, but also because operating environments are improving as these countries open up to global trade.Features and benefits* Overview of drivers, resistors and trends within the Asia Pacific M&A landscape.* Summary of geographic M&A activity on a regional and country-specific basis.* Analysis of the types of acquisitions and healthcare sectors targeted.* Examination of transaction values and leading dealmakers.HighlightsIndia, Japan and Australia all continued to record frequent deal activity, although China increased its lead in terms of total deal numbers in 2010 and early 2011. However, Chinese companies continue to focus primarily on domestic transactions.Japanese companies still account for the majority of M&A deal value. The first half of 2011 has already surpassed previous peak M&A deal values in APAC, continuing the annual upward trend seen in transaction values when outlying multi-billion dollar deals are excluded.While most M&As involving APAC-based players target pharmaceutical and biological products companies, such as generics and active pharmaceutical ingredient (API) manufacturers, medical devices and equipment firms have recently taken over as the leading sector targeted for M&A.Your key questions answered* Which are the most highly valued pharmaceutical sectors for acquirers, and which companies have been the most acquisitive in APAC in recent years'* Which APAC markets have been most frequently targeted through M&As, and which have attracted the attention of Big Pharma'

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Pharmaceutical M&A in the Asia Pacific Region
Published on November 2011
Report Summary
Introduction
Slowing growth continues in major developed markets, prompted by generic erosion of branded sales and increasing regulatory and
cost containment pressures. Expansion into emerging Asia Pacific (APAC) markets is appealing not only because of their rapid
growth and sizeable patient populations, but also because operating environments are improving as these countries open up to global
trade.
Features and benefits
* Overview of drivers, resistors and trends within the Asia Pacific M&A landscape.
* Summary of geographic M&A activity on a regional and country-specific basis.
* Analysis of the types of acquisitions and healthcare sectors targeted.
* Examination of transaction values and leading dealmakers.
Highlights
India, Japan and Australia all continued to record frequent deal activity, although China increased its lead in terms of total deal
numbers in 2010 and early 2011. However, Chinese companies continue to focus primarily on domestic transactions.
Japanese companies still account for the majority of M&A deal value. The first half of 2011 has already surpassed previous peak M&A
deal values in APAC, continuing the annual upward trend seen in transaction values when outlying multi-billion dollar deals are
excluded.
While most M&As involving APAC-based players target pharmaceutical and biological products companies, such as generics and
active pharmaceutical ingredient (API) manufacturers, medical devices and equipment firms have recently taken over as the leading
sector targeted for M&A.
Your key questions answered
* Which are the most highly valued pharmaceutical sectors for acquirers, and which companies have been the most acquisitive in
APAC in recent years'
* Which APAC markets have been most frequently targeted through M&As, and which have attracted the attention of Big Pharma'
Table of Content
Executive Summary
Introduction
Strategic scoping and focus
Key findings
M&A in APAC are driven by slowing growth in major markets and domestic consolidation
Pharmaceutical M&A in the Asia Pacific Region (From Slideshare) Page 1/5

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Acquisitions are often used to gain a foothold in new Asian markets, where better healthcare is driving increased demand for
quality Western medicines
China, India, and Japan continue to dominate M&A activity in the APAC region
Key definitions
Company classifications
Acquisition types
Geographic classifications
Other
Related reports
Upcoming related reports
OVERVIEW OF M&A ACTIVITY
Key findings
Drivers and resistors of APAC M&A
Stronger growth forecast in emerging compared to developed markets
Changing socio-demographics create patient demand for better healthcare
Policy and regulation changes are creating a more certain business environment in APAC markets
Product development costs are rising rapidly in developed markets, particularly for clinical trials
Overview of M&A activity by geography
China is the most common target location for acquisitions
Chinese companies are the most common acquirers
India is the leading APAC target for top ranking pharma companies, but China is catching up
Domestic and intra-APAC deals still dominate in the region
Overview of M&A activity by deal type and size
100% acquisitions are the principal deal type involving APAC companies
Minority acquisitions are not common, but are often used to solidify other types of relationships
Acquisitions of complete business units are the most common form of asset purchase
M&A were performed by existing shareholders in a quarter of deals analyzed
M&A value is likely to reach the highest annual levels in 2011
The value of 100% acquisitions has been rising year-on-year in APAC
Overview of M&A activity by healthcare sector and therapy area
Therapeutics-focused companies are the most common APAC M&A targets
Medical technology is the most frequent target sector for M&A
Leading pharma players differ slightly in their targeted sectors
Acquirers target highest value and volume therapeutic areas
COUNTRY-SPECIFIC M&A ACTIVITY
Key findings
APAC markets with significant M&A activity
Chinese companies continued to focus on mainly domestic M&A activity
M&A activity in India is inconsistent on an annual basis
Japanese companies dominated APAC M&A activity in terms of deal value
Australian assets attracted significant international investment
APAC markets with moderate M&A activity
Singaporean companies have become more frequent targets for M&A
M&A activity in South Korea increased consistently to 2010
New Zealand attracted M&A partners from only a limited number of developed markets
Malaysian M&A deals are slowly increasing in frequency
The largest proportion of M&A deals in Taiwan took place in 2008
Other APAC countries were involved in few M&A deals
Pharmaceutical M&A in the Asia Pacific Region (From Slideshare) Page 2/5

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Foreign M&A in Thailand was based on pre-existing relationships
Only other APAC-based companies sought deals in the Philippines
Indonesia's single deal involved the sale of a local Big Pharma subsidiary
Vietnam is still emerging as an M&A target
BIBLIOGRAPHY
Publications and online articles
Company press releases
Datamonitor products
APPENDIX
Methodology
Key definitions
Company classifications
Acquisition types
Geographic classifications
Other
Exchange rates
Pharmaceutical M&A in the Asia Pacific Region (From Slideshare) Page 3/5

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Pharmaceutical M&A in the Asia Pacific Region
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 7 600.00 Quantity: _____
Corporate License--USD 19 000.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Pharmaceutical M&A in the Asia Pacific Region (From Slideshare) Page 4/5

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Pharmaceutical M&A in the Asia Pacific Region (From Slideshare) Page 5/5